Invitae - NVTA Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 sell ratings and 9 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View NVTA analyst ratings or view top-rated stocks.

12 brokerages have issued twelve-month price objectives for Invitae's shares. Their NVTA share price forecasts range from $2.80 to $18.00. On average, they expect the company's stock price to reach $8.04 in the next year. This suggests a possible upside of 196.8% from the stock's current price.
View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts.

Invitae's stock was trading at $15.27 at the beginning of the year. Since then, NVTA shares have decreased by 82.3% and is now trading at $2.71.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NVTA earnings forecast.

Invitae Co. (NYSE:NVTA) posted its earnings results on Tuesday, November, 8th. The medical research company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.17. The medical research company earned $133.54 million during the quarter, compared to analyst estimates of $132.80 million. Invitae had a negative trailing twelve-month return on equity of 39.04% and a negative net margin of 617.65%.

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Invitae's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.95%), Vanguard Group Inc. (8.90%), Sumitomo Mitsui Trust Holdings Inc. (7.34%), Fisher Asset Management LLC (1.30%), State of Michigan Retirement System (0.83%) and Polar Asset Management Partners Inc. (0.70%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends.

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVTA stock can currently be purchased for approximately $2.71.

Invitae (NYSE:NVTA) has a market capitalization of $658.26 million and generates $460.45 million in revenue each year. The medical research company earns $-379,010,000.00 in net income (profit) each year or ($13.84) on an earnings per share basis.

The company employs 3,000 workers across the globe.

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (415) 374-7782 or via email at ir@invitae.com.